HAYWARD, Calif.--(BUSINESS WIRE)--IMPAX Laboratories, Inc. today announced Boehringer Ingelheim Pharmaceuticals Inc. (“Boehringer”) and Astellas Pharma Inc. (“Astellas”) have filed suit for patent infringement in the United States District Court for the Northern District of California based on the Company’s submission of Abbreviated New Drug Application (“ANDA”) for tamsulosin hydrochloride capsules (0.4 mg), generic of Flomax®, to the Food and Drug Administration. In connection with this ANDA, IMPAX provided notice to Boehringer and Astellas that its submission includes a Paragraph IV certification stating the Company believes its product does not infringe any valid or enforceable claim of U.S. Patent No. 4,703,063.
